Navigation Links
Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
Date:2/22/2012

AMARILLO, Texas, Feb. 22, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that Dr. Stephen T. Chen has been appointed as Chairman of the Board and Chief Executive Officer.  Dr. Joseph Cummins will remain as President and become Chief Operating Officer. Dr. Chen has been a director of the company since February 1996. He received a PhD degree in Industrial and Physical Pharmacy from Purdue University in 1977 with an emphasis on drug delivery systems.

Dr. Chen has over thirty years of international business experience, including an extensive background in pharmaceutical product acquisition and licensing, development of joint venture agreements, execution of business strategy, and leadership of start-up companies in the pharmaceutical, biotechnology and nutraceutical industries. Dr. Chen has held executive positions in R&D and business development at several major pharmaceutical companies, including Burroughs Wellcome (presently GlaxoSmithKline), Miles Pharmaceuticals (presently Bayer), ICI America (presently AstraZeneca), and Ciba-Geigy (presently Novartis).

About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 4% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010. 

Investor Relations: Philippe Niemetz

PAN Consultants, Ltd.

e-mail:p.niemetz@panconsultants.com
Tel: 212-344-6464

Fax: 212-618-1276

 

Joseph M. Cummins

President and COO

e-mail: jcummins@amarbio.com

Tel: 806-376-1741

Fax: 806-376-9301

 


'/>"/>
SOURCE Amarillo Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Issues Corporate Update
2. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
3. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... ... that Ardy Arianpour has joined the company as Chief Business Officer. Arianpour, a ... innovative genomic technologies to market, was most recently Chief Commercial Officer of Pathway ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO business for ... multi-million dollar, multi-year managed services contract in the U.S. intelligence community with The SI ... team,” said John Younger, founder of Accolo. “We are growing and his experience ...
(Date:4/26/2016)... ... 2016 , ... Seattle based non-profit, The Institute for Venture ... The grant will be used to further the scientific research goals of the ... http://www.ivsci.org , In accounting the grant to the IVS, Mr. Glenn Estrabillo ...
(Date:4/26/2016)... ... April 26, 2016 , ... ... the opening of its first round of pre-proposal competition for scientific grants. , ... seeks to identify ideas with the highest potential to replace paradigms that have ...
Breaking Biology Technology:
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/17/2016)... March 17, 2016 ABI Research, the ... the global biometrics market will reach more than ... increase from 2015. Consumer electronics, particularly smartphones, continue ... sensors anticipated to reach two billion shipments by ... Dimitrios Pavlakis , Research Analyst at ABI Research. ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... Images ( http://www.apimages.com ) - Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ... Hanover next week.   --> Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ...
Breaking Biology News(10 mins):